CORRECTIONS

Journal Corrections

The April 1, 2010, article by Satoh et al, entitled, “Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection” (J Clin Oncol 28:1727-1732, 2010), contained an error in the online version.

In the Abstract, Results section, the third sentence indicated that 5-year overall survival for patients with stage IA and favorable histology was 10%, whereas it should have been 100% as follows:

“Five-year overall survival and recurrence-free survival were **100%** and 97.8% for stage IA and favorable histology

(n = 108), 100% and 100% for stage IA and clear cell histology (n = 15), 100% and 33.3% for stage IA and grade 3 (n = 3), 96.9% and 92.1% for stage IC and favorable histology (n = 67), 93.3% and 66.0% for stage IC and clear cell histology (n = 15), and 66.7% and 66.7% for stage IC and grade 3 (n = 3).”

Journal of Clinical Oncology apologizes to the authors and readers for the mistake.

DOI: 10.1200/JCO.2011.40.5563

The October 1, 2011, ASCO special article by Azzoli et al, entitled, “2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer” (J Clin Oncol 29:3825-3831, 2011), contained an error.

In Table 1, under Recommendation C, Third-line chemotherapy, the word “these” should have been included in the summary for Recommendation C2 as follows:

“Data are not sufficient to make recommendation for or against using cytotoxic drug as third-line therapy; **these** patients should consider experimental treatment, clinical trials, and best supportive care.”

The online version has been corrected in departure from the print. *Journal of Clinical Oncology* apologizes to the authors and readers for the mistake.

DOI: 10.1200/JCO.2011.40.5571

The November 1, 2011, article by Brugger et al, entitled, “Prospective Molecular Marker Analyses of *EGFR* and *KRAS* From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer” (J Clin Oncol 29:4113-4120, 2011), contained errors.

In the Abstract, Conclusion section, the second and third sentences were given as: “No other biomarkers were predictive for outcomes with erlotinib, although the study was not powered for clinical outcomes in biomarker subgroups. *EGFR* IHC–positive *KRAS* mutations were prognostic for reduced PFS.”

Whereas they should have read:

“No other biomarkers were predictive for outcomes with erlotinib, although the study was not powered for clinical outcomes in biomarker subgroups **other than** *EGFR* IHC–positive. *KRAS* mutations were prognostic for reduced PFS.”

The authors and *Journal of Clinical Oncology* apologize to the readers for the mistakes.

DOI: 10.1200/JCO.2011.40.5589